Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Thromboxane signalling links immune activation to enhanced glucose uptake in skeletal muscle
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2026 (English)In: Diabetologia, ISSN 0012-186X, E-ISSN 1432-0428, Vol. 69, p. 1643-1658Article in journal (Refereed) Published
Abstract [en]

Aims/hypothesis: Exercise elicits a spectrum of metabolic and inflammatory responses that are crucial for skeletal muscle adaptation and overall health, particularly in the context of metabolic diseases, yet the contribution of prostanoid signalling to these processes remains unclear. We hypothesised that exercise-induced thromboxane production enhances skeletal muscle glucose uptake and improves whole-body glucose control.

Methods: Plasma prostanoids were quantified in men and women with normal glucose tolerance or type 2 diabetes before, immediately after and 3 h after a single bout of exercise. Cyclooxygenase (COX-2) transcript levels were evaluated in human skeletal muscle, whole blood, peripheral blood mononuclear cells and skeletal muscle-resident immune cells. Metabolic and transcriptomic effects of thromboxane receptor activation were analysed in mouse C2C12, rat L6 and human primary skeletal muscle cells. Glucose tolerance in vivo was assessed following i.p. administration of the thromboxane receptor agonist I-BOP in male and female mice. Tissue-specific glucose uptake was quantified by measuring radiolabelled 2-deoxyglucose incorporation during an IVGTT.

Results: Acute exercise increased plasma thromboxane B₂ concentrations and skeletal muscle mRNA levels of PTGS2 (encoding COX-2) selectively in monocyte/macrophage populations. In skeletal muscle cells, the thromboxane receptor agonist I-BOP increased glucose uptake in a dose-dependent manner up to 2.5-fold within 4 h and enhanced glycogen synthesis by 430%. Transcriptomic and signalling analysis revealed activation of protein kinase A and cytoskeletal remodelling pathways linked to GLUT4 trafficking. In vivo, I-BOP improved glucose tolerance in male mice in a dose-dependent manner, without altering insulin levels. Thromboxane receptor stimulation increased glucose uptake in extensor digitorum longus muscle by 43%. Importantly, thromboxane receptor activation preserved its glucose-lowering efficacy in diet-induced obese male mice.

Conclusions/interpretation: Exercise induces skeletal muscle-derived thromboxane production through macrophage-specific COX-2 activation. Thromboxane receptor stimulation enhances glucose uptake and glycogen storage via cytoskeletal remodelling, partially mimicking the acute exercise transcriptomic response. In vivo, thromboxane receptor activation improves glucose tolerance and skeletal muscle glucose uptake, with preserved efficacy in obesity. These findings identify thromboxane signalling as a previously unrecognised immunometabolic axis linking inflammation to glucose regulation and highlight the thromboxane receptor as a potential therapeutic target for metabolic disease.

Place, publisher, year, edition, pages
Springer, 2026. Vol. 69, p. 1643-1658
Keywords [en]
Exercise, Glucose, Metabolism, Skeletal muscle, Thromboxane, Type 2 diabetes
National Category
Physiology and Anatomy Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:umu:diva-250523DOI: 10.1007/s00125-026-06684-8ISI: 001694875600001PubMedID: 41714436Scopus ID: 2-s2.0-105030584700OAI: oai:DiVA.org:umu-250523DiVA, id: diva2:2047253
Funder
AstraZenecaKnut and Alice Wallenberg Foundation, KAW 2023.0312Swedish Research Council, 2022-00609Swedish Research Council, 2015-00165Novo Nordisk Foundation, NNF22OC0077741Novo Nordisk Foundation, NNF24SA0092609Diabetesfonden, DIA2021-641Diabetesfonden, DIA2023-824EU, European Research Council, ERC-2023-AdG 101142093Region StockholmAvailable from: 2026-03-19 Created: 2026-03-19 Last updated: 2026-05-21Bibliographically approved

Open Access in DiVA

fulltext(2104 kB)3 downloads
File information
File name FULLTEXT02.pdfFile size 2104 kBChecksum SHA-512
42031b60c3ce9d2bcdd9acfb5b2c033728add5f9f74bbfaaf034afbe785a8768a308201781cbf6c739b5e536ead24286b0abcb1eedc4b426e35934ba8a3b09b7
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Olsson, TommyOtten, Julia

Search in DiVA

By author/editor
Olsson, TommyOtten, Julia
By organisation
Department of Public Health and Clinical Medicine
In the same journal
Diabetologia
Physiology and AnatomyEndocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 35 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 478 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf